Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.

Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.

Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.

Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.

Abstract: A bioerodible patch comprising at least one bioadhesive layer and at least one non-bioadhesive layer, wherein the bioadhesive layer comprises at least one polyaphron dispersion and at least one bioadhesive polymer, and wherein the polyaphron dispersion comprises at least one pharmaceutically active agent.

Abstract: A bioerodible patch comprising at least one bioadhesive layer and at least one non-bioadhesive layer, wherein the bioadhesive layer comprises at least one polyaphron dispersion and at least one bioadhesive polymer, and wherein the polyaphron dispersion comprises at least one pharmaceutically active agent.

Abstract: A method of coating the surface of a substrate which comprises the steps of: i) contacting the surface with a polymerisable mixture comprising one or more polymerisable components and containing suspended droplets of a biliquid foam or of a high internal oil phase emulsion, the said droplets being stabilised by a non-reactive surfactant; and ii) polymerising the coating to form a polymer comprising the droplets entrapped therein.

Abstract: A discrete powder which comprises particles in which a biliquid foam has been entrapped with a matrix of a polymeric material. A process for the preparation of these discrete powders comprises the steps of: i) preparing a biliquid foam, ii) forming a dispersion of the biliquid foam in an aqueous solution, suspension or dispersion of a polymeric material, and iii) subjecting the dispersion to drying under conditions such that a discrete powder is formed.

Abstract: A fuel composition which comprises a biliquid foam consisting of from 10% to 97.5% by weight of non-coalescing droplets of a non-polar liquid comprising a petroleum derivative, paraffin or a liquid halogenated hydrocarbon and from 2 to 87% by weight of a continuous phase polar liquid comprising a C1-C3 alcohol, a C4 alcohol containing at least two hydroxy groups, or ethylene glycol, or mixtures thereof, in an amount of from 60% to 100% by weight thereof, wherein the biliquid foam is stabilized with an amount of from 0.5 to 3.0% by weight based on the total formulation of a surfactant which is selected from castor oil/poly(alkylene glycol) adducts containing from 20 to 50 alkoxy groups, or hydrogenated castor oil/poly(alkylene glycol) adducts containing from 20 to 60 alkoxy groups, or mixtures thereof.